These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 38124750)
1. Mesenchymal stem cell-derived exosomes can alleviate GVHD and preserve the GVL effect in allogeneic stem cell transplantation animal models. Jiang Y; Zhao J; Wang M; Huang F; Li J; Liu R; Wan J; Hao S Front Immunol; 2023; 14():1284936. PubMed ID: 38124750 [TBL] [Abstract][Full Text] [Related]
2. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation. Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747 [TBL] [Abstract][Full Text] [Related]
3. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia. Oviedo A; Yañez R; Colmenero I; Aldea M; Rubio A; Bueren JA; Lamana ML Cell Transplant; 2013; 22(8):1381-94. PubMed ID: 23044223 [TBL] [Abstract][Full Text] [Related]
4. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Tian Y; Deng YB; Huang YJ; Wang Y Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798 [TBL] [Abstract][Full Text] [Related]
5. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799 [TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view. Shafeghat Z; Dorfaki M; Dehrouyeh S; Arab FL; Roozbehani M; Falak R; Faraji F; Jafari R Transpl Immunol; 2023 Dec; 81():101957. PubMed ID: 37935319 [TBL] [Abstract][Full Text] [Related]
7. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
8. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation. Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844 [TBL] [Abstract][Full Text] [Related]
9. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models. Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502 [TBL] [Abstract][Full Text] [Related]
10. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M Front Immunol; 2020; 11():593863. PubMed ID: 33324410 [TBL] [Abstract][Full Text] [Related]
11. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice. Jang MJ; Kim HS; Lee HG; Kim GJ; Jeon HG; Shin HS; Chang SK; Hur GH; Chong SY; Oh D; Chung HM Acta Haematol; 2013; 129(4):197-206. PubMed ID: 23257958 [TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model. Gil S; Im KI; Kim N; Lee J; Na H; Min GJ; Cho SG Int J Med Sci; 2024; 21(9):1649-1660. PubMed ID: 39006841 [TBL] [Abstract][Full Text] [Related]
13. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA Front Immunol; 2019; 10():295. PubMed ID: 30891031 [TBL] [Abstract][Full Text] [Related]
14. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations. Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913 [TBL] [Abstract][Full Text] [Related]
15. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation. Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats. Kitazawa Y; Li XK; Xie L; Zhu P; Kimura H; Takahara S Cell Transplant; 2012; 21(2-3):581-90. PubMed ID: 22793067 [TBL] [Abstract][Full Text] [Related]
17. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558 [TBL] [Abstract][Full Text] [Related]
18. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model. Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360 [TBL] [Abstract][Full Text] [Related]
19. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489 [TBL] [Abstract][Full Text] [Related]
20. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H Front Immunol; 2021; 12():785774. PubMed ID: 34987512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]